


...and *Lilly* provides the sedatives
to suit the individual



So embracing is the range of LILLY barbiturates that it is simple to select the form of sedation that is *exactly* suited to the patient's individual needs.

'SECONAL SODIUM'

BRAND
QUINALBARBITONE SODIUM

When rapid action with brief duration is called for

'SODIUM AMYTAL'

BRAND
SODIUM AMYLOBARBITONE

For routine sedation in the anxiety case

'TUINAL'

BRAND
QUINALBARBITONE SODIUM
WITH SODIUM AMYLOBARBITONE

In the chronic insomnia case

'AMYTAL'

BRAND
AMYLOBARBITONE

Sedation in the hypertensive, peptic ulcer, skin or cardiac case

*Let it be a *Lilly* barbiturate*

* TRADE MARK

ELI LILLY AND COMPANY LIMITED · BASINGSTOKE · ENGLAND

JOURNAL OF MENTAL SCIENCE

CONTENTS FOR JULY, 1959

Original Articles—

	PAGE
The Thirty-third Maudsley Lecture: Trends in Child-Psychiatry; by <i>Leo Kanner, M.D.</i>	581
The Origin and Spread of Dementia Paralytica; by <i>E. H. Hare, M.A., M.D., D.P.M.</i>	594
An Experimental Study of Schizophrenic Thought Disorder; by <i>R. W. Payne, B.A., Dip.Psych., Ph.D., P. Mattussek, M.D., Ph.D.(Dozent), and E. I. George, M.A., Ph.D.</i>	627
Schizophrenia: A New Approach (continued); by <i>H. Osmond, M.R.C.S., D.P.M., and A. Hoffer, Ph.D., M.D.</i>	653
Indoluria in Schizophrenia; by <i>A. D. Forrest</i>	
I. Statistical Study and Investigation of Hepatic Function	674
II. Chromatographic Study on 40 Schizophrenic and 10 Normal Subjects	685
Prognostic Factors in the Electroshock Treatment of Depressive States; by <i>Julian M. Roberts, M.D., D.P.M.</i>	
I. Clinical Features from History and Examination	693
II. The Application of Specific Tests	703
Observations on the Pathology of Insidious Dementia Following Head Injury; by <i>J. A. N. Corsellis and J. B. Brierley</i>	714
Microcephaly; by <i>M. W. G. Brandon, B.A., Dip.Ed., Brian H. Kirman, M.D., D.P.M., and Cyril E. Williams, M.B., Ch.B., D.P.M.</i>	721
Liver Damage in Addictive Alcoholics; by <i>W. W. Kay, M.Sc., M.B., Ch.B., F.R.I.C., K. C. Murfitt, M.Sc., and M. M. Glatt, M.D., D.P.M.</i>	748
Some Criticisms of Factor Analysis with Suggestions for Alternative Methods; by <i>Monica A. Creasy, B.Sc.</i>	755
The Clinical Use of Stilboestrol for Suppression of Sexual Behaviour of Chronically Ill Male Psychiatric Patients; by <i>John D. Adamson</i>	762
Effects of 5-Hydroxytryptophan on Schizophrenia; by <i>J. C. Brengelmann, M.D., Ph.D., C. M. B. Pare, M.D.(Camb.), M.R.C.P., D.P.M., and M. Sandler, M.B.(Manch.), M.R.C.P.</i>	770
Studies in Schizophrenia—VI: Paper Chromatography of Urinary Indoles and the "Glyoxylic Acid" Reaction; by <i>H. H. Fleischhacker and J. B. Lancaster</i>	777
The Relative Stability of Personality Measures compared with Diagnostic Measures; by <i>E. A. Foulds, M.A., Ph.D.</i>	783
Observations on Arousal following Megimide (Bemegride) During Light Barbiturate Narcosis; by <i>Brian Ackner, M.A., M.D.(Camb.), M.R.C.P., D.P.M., and G. Pampiglione, M.D.(Rome), M.R.C.P.</i>	788
Hydroxyzine (Atarax) in the Relief of Tension Associated with Anxiety Neurosis and Mild Depressive States; by <i>R. Middlefell, M.B., Ch.B., D.P.M., and K. C. S. Edwards, M.R.C.S., L.R.C.P., D.P.M.</i>	792
Deliberate Re-hypnotization after the Patient's Refusal; by <i>Ian Oswald, M.A., M.D.</i>	795
Phenothiazine Toxicity, Extrapyramidal Seizures, and Oculogyric Crises; by <i>George Paulson, M.D.</i>	798
Admission to Mental Hospital after Thyroidectomy—Observations on a Series of Cases; by <i>Kingsley Jones, L.R.C.P. & S.I., D.P.M.(Eng.)</i>	803
The Predictive Validity of a Psychological Test of Brain-Damage; by <i>D. Walton and D. A. Black</i>	807
A Controlled Study of the Effectiveness of Trifluopromazine Hydrochloride; by <i>J. G. Hegarty, M.B., Ch.B., D.P.M., and A. R. Dabbs, B.A., Dip.Psych.</i>	811
A Short Scale for Rating Paranoid Schizophrenia; by <i>P. H. Venables, Ph.D., and N. O'Connor, Ph.D.</i>	815
Anticonvulsants and Megaloblastic Anaemia; by <i>John Johnson, M.B., Ch.B.</i>	819
Changes in Catechol Amine Response to Successive Electric Convulsive Treatments; by <i>Leston L. Havens, M.D., M. Sherif Zileli, M.D., Alberto DiMascio, M.A., Lenore Boling, M.D., and Alan Goldfien, M.D.</i>	821
A Case of Phocomelia associated with Severe Mental Deficiency; by <i>Frederick Edward Kratter, B.Sc., M.B., Ch.B., D.P.M.</i>	830
Cutis Anserina: Its Significance in the Prognosis of Mental Illness; by <i>Leston L. Havens, M.D., J. Frank Hart and John E. Cavte, M.D.</i>	833
Emotion and Blood-Pressure; by <i>George Innes, M.B., Ch.B., D.P.H., W. Malcolm Millar, M.D., D.Psych., and Max Valentine, M.D., D.P.M.</i>	840
A Controlled Trial of Ethylcrotonylurea; by <i>J. P. Baker, M.B., M.R.C.S., D.P.M.</i>	852
The Effect of Electro-convulsive Therapy on Initiative; by <i>G. H. Collins, M.D., D.P.M., and M. Bassett, Dip. Soc. Sci.</i>	863
The Validity of the Mechl M.M.P.I. Psychotic Scale in the Diagnosis of Schizophrenia; by <i>Donald Walton, Marcia Mather and D. A. Black</i>	869
A Comparison of Perphenazine ("Fentazin") Sodium Amylobarbitone and a Placebo in Anxious and Depressed Out-Patients; by <i>J. M. Hinton, M.B., M.R.C.P., D.P.M.</i>	872

Printed in Great Britain by Headley Brothers Ltd 100 Kingsway London WC2 and Ashford Kent

